REMINDER: Our focusIR Investor Webinar takes place TONIGHT with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMXC.L Share News (MXC)

  • There is currently no data for MXC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SMALL-CAP WINNERS & LOSERS: MGC Pharma drops on restructuring plan

Tue, 26th Sep 2023 09:52

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Tuesday.

----------

SMALL-CAP - WINNERS

----------

Synthomer PLC, 805.81 pence, multiplied from 40.30p, 12-month range 40.76-898.56p. The chemicals company announces that, following the approval of a capital reorganisation at a general meeting, 23.4 million of its shares have been admitted to trading on the London Stock Exchange. Explains that, as part of the capital organisation, its existing shares have been consolidated so that shareholders will receive consolidated shares on a ratio of 1 consolidated share in substitution for every 20 existing shares.

----------

SMALL-CAP - LOSERS

----------

MGC Pharmaceuticals Ltd, down 48% at 0.055 pence, 12-month range 0.050-0.98p. The pharmaceutical company says it finds itself at a "critical financial juncture" due to "underwhelming" fundraising efforts and the failure of its share price to appreciate. As a result, says it has been forced to design a restructuring plan to secure long-term financing. Says the plan will reduce its reliance on "constant" capital raising and allow it to complete an 18-month work plan. "We understand this restructure will be difficult for many shareholders. However, in light of dire alternatives, the board and management believe this is a necessary action to help to sustain the company's future and financial security beyond the short to immediate term," Managing Director Roby Zomer says.

----------

Videndum PLC, down 28% at 394.27 pence, 12-month range 385.00-1,360.00p. The hardware product and software solutions provider reports a sharp drop in profit in the first half of 2023 amid a number of ongoing macroeconomic headwinds. In the six months ended June 30, Videndum reports a pretax profit of GBP3.1 million, down sharply from GBP22.9 million the year prior. Revenue in the half falls to GBP165.0 million from GBP219.4 million. Company blames the drop in profit on ongoing macroeconomic headwinds, the effects of destocking the writers' strike in the US. Adds that given the ongoing strikes in the US, there will be no interim dividend. Plans to resume dividend payments "when appropriate." Looking forward, says there is a "wide range" of potential outcomes for the full-year due to the strikes and thus is unable to provide financial guidance. Separately, Videndum announces that Chair Ian McHoul will not stand for re-election at the company's 2024 annual general meeting. The search for his replacement begins.

----------

Card Factory PLC, down 5.3% at 105.28 pence, 12-month range 40.21-117.00p. The greeting card retailer says that in the six months ended July 31, pretax profit rises to GBP24.7 million from GBP14.3 million the year prior. Revenue climbs to GBP220.8 million from GBP198.0 million. Less positively, cost of sales rise to GBP139.5 million from GBP132.2 million and operating expenses rise to GBP53.2 million from GBP45.8 million. Card Factory says it is "confident" in delivering a good outturn for the year following the strength of its first half performance. Notes that trading since August has been in line with its expectations.

----------

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
1 Sep 2022 17:52

TRADING UPDATES: Strong interim results from Johnson Service, Eurocell

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Aug 2022 16:26

TRADING UPDATES: Malvern revenue jumps; Rockwood eyes Main Market

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
18 Aug 2022 11:57

IN BRIEF: Graft Polymer wins first commercial order for GraftBio

Graft Polymer (UK) PLC - London-based company focused on the development and production of polymer modification, biological supplements, and nano-drug delivery systems - Wins first commercial purchase order for its GraftBio division. Order for 50,000 units of its anti-inflammatory supplement, ArtemiC Rescue from MGC Pharmaceuticals PLC. Order worth around USD1 million. Production to start immediately. Delivery expected over the next three months. Chief Executive Victor Volduev says he expects follow-on orders in the coming quarters.

Read more
17 Aug 2022 11:12

MGC shares rise on USD1 million order for ArtemiC

(Alliance News) - MGC Pharmaceuticals Ltd shares were lifted on Wednesday after it announced a USD1 million order for its neutraceutical, ArtemiC.

Read more
15 Aug 2022 17:31

IN BRIEF: MGC Pharma's CannEpil found safe for driving in study

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says clinical study results for its epilepsy treatment, CannEpil, are complete. The study found CannEpil to be safe for post-treatment driving activities. It used a driving simulator to test whether the drug caused somnolence, ie drowsiness, or impairs cognition. It was sponsored by Cannvalate Australia, and conducted by the Centre of Human Psychopharmacology at Swinburne University of Technology, under the Medical Cannabis Research Collaboration.

Read more
5 Aug 2022 14:58

TRADING UPDATES: 4D Pharma warns of wind-up; Star Phoenix files claim

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Wednesday and not separately reported by Alliance News:

Read more
29 Jul 2022 19:36

TRADING UPDATES: Walker Crips assets grow; Minoan interim loss narrows

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
28 Jul 2022 20:08

TRADING UPDATES: Scottish American outperforms; Amte picks Dundee

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Jul 2022 21:53

IN BRIEF: MGC Pharmaceuticals quarterly sales "strong"

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says "strong" quarterly sales continue, notes AUD1.6 million, about GBP923,000, in cash receipts during three month period to June 30. In 12-month period, records AUD6.1 million in cash receipts.

Read more
14 Jul 2022 21:44

TRADING UPDATES: Shield closer to Canada approval; Angle plans raise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
8 Jul 2022 14:19

IN BRIEF: MGC Pharmaceuticals wins approval for Covid study, shares up

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Receives approval from South African Health Products Regulatory Authority for a Phase 2b dose finding study of its nanoparticle formulation CimetrA on patients diagnosed with Covid-19.

Read more
6 Jul 2022 20:08

IN BRIEF: MGC Pharmaceuticals launches medical data app ZAM

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says it is set to launch a real-time data collection application, ZAM, for use across the pharmaceutical and health care sectors, in collaboration with software development company, Caba Tech. The app will be available during the third quarter and will enable patients to log their medical history and monitor their medication use. ZAM, through the collection the patient data, will also provide users with a more complete understanding of their health and treatments, it says.

Read more
27 Jun 2022 20:27

IN BRIEF: MGC's CimetrA shows promise beyond Covid applications

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says preliminary results from pre-clinical in vitro study of CimetrA show it could have "wide-ranging application" as anti-inflammatory treatment. This is through the treatment's modulation of the production of pro-inflammatory cytokines. The study was undertaken by Israeli contract research organisation, Science in Action. Results support previous findings from a 2020 study into Covid-19, which showed CimetrA modulates the body's production of cytokines, which can lead to a cytokine storm, a type of severe immune reaction. New results support the potential of CimetrA to have a wider-ranging application as anti-inflammatory treatment, beyond the treatment of Covid-19 symptoms.

Read more
24 Jun 2022 10:13

IN BRIEF: MGC Pharma moves ahead with Covid-19 treatment in US

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Progresses plans to begin US clinical trial for its Covid-19 treatment CimetrA, as MGC and AMC Holdings Inc executives meet with department heads from the University of South Florida. Parties also discuss regulatory approvals for phytocannabinoid medicines CogniCann and CannEpil in the US for early patient access schemes. Says US market access and distribution agreement has been signed with minimum orders of USD24 million over three years, including CimetrA.

Read more
16 Jun 2022 13:43

IN BRIEF: MGC Pharmaceuticals completes research study on brain cancer

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Completes an in-vitro preclinical research study with the National Institute of Biology into the use of cannabinoids to treat brain cancer. The company says the study, undertaken on 30 biopsy samples from 18 patients over a period of three years, sought to determine the optimal formulation for the treatment of Glioblastoma, a form of brain cancer. The study showed that MGC Pharma's proprietary formulations were cytotoxic to Glioblastoma tumour and stem cells, reducing the cells' viability and inducing caspase-dependent cell apoptosis, or cell death.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.